股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年12月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 粵海廣南(集團)有限公司 | | | 呈交日期: | 2026年1月5日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01203 | 說明 | | 不適用 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 907,593,285 | | 0 | | 907,593,285 | | 增加 / ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部 份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：01203） 《上市規則》之涵義 於本公告日期，香港粵海持有本公司已發行股份總數約59.19%，因此香港粵海為 本公司之主要股東及關連人士。此外，香港粵海持有粵海投資已發行股份總數約 58.26%，且粵海能源服務為粵海投資之非全資附屬公司（因此亦為香港粵海之非全 資附屬公司），故粵海能源服務為香港粵海之聯繫人及本公司之關連人士。由於粵 海中粵、粵海食品佛山、潤和合食品及廣龍食品均為本公司之附屬公司，因此2026 年電力合同及其項下擬進行之交易構成《上市規則》第14A章項下本公司之持續關 連交易。 1 基於每份2026年電力合同均涉及本公司的附屬公司向粵海能源服務購買電力並於 同日訂立，2026年電力合同項下擬進行之交易已根據《上市規則》進行合併計算。 由於建議上限之所有適用百分比率超過0.1%但低於5%，故2026年電力合同、其項下 擬進行之交易及建議上限須遵守 ...

| 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 粵海廣南(集團)有限公司 | | | 呈交日期: | 2025年12月1日 | | | I. 法定/註冊股本變動 不適用 | | | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 II. 已發行股份及/或庫存股份變動 FF301 第 1 頁 共 10 頁 v 1.1.1 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01203 | 說明 | | 不適用 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 907,593,285 | | 0 | | 907,593,285 | | 增加 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 條款之重大變更 條款之重大變更 茲提述本公司日期為2023年4月25日內容有關根據原合夥協議成立有限合夥企業 的該公告。除另有界定者外，本公告所用詞彙與該公告所界定者具有相同涵義。 於2025年11月28日，粵海廣南投資（為本公司直接全資附屬公司）（作為有限合夥 人）與粵海投資基金（作為普通合夥人、執行事務合夥人及管理人）及粵海資本集 團（作為有限合夥人）就營運及管理有限合夥企業訂立新合夥協議，據此，原合夥 協議的若干條款有所變更，詳情於本公告披露。 除本文所披露者外，概無對原合夥協議作出其他重大變更。 – 1 – 上市規則的涵義 香港粵海為本公司之控股股東，持有本公司已發行股份總數約59.19%。香港粵海 為粵海控股的全資附屬公司。由於粵海投資基金（為普通合夥人、執行事務合夥 人及管理人）為粵海控股的全資附屬公司，為香港粵海之同系附屬公司，故為香 港粵海的聯繫人，因此根據上市規則為本公司之關連人士。此 ...

| 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01203 | 說明 | | 不適用 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 907,593,285 | | 0 | | 907,593,285 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 907,593,285 | | 0 | | 907,593,285 | 第 2 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 粵海廣南(集團)有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 不適用 FF301 第 1 頁 ...

Core Viewpoint - Guangnan Group (01203) reported a revenue of HKD 9.452 billion for the first three quarters, representing a year-on-year increase of 10%, while the profit attributable to shareholders was HKD 109 million, a decrease of 6% compared to the previous year [1] Financial Performance - Revenue for the first three quarters reached HKD 9.452 billion, marking a 10% year-on-year growth [1] - Profit attributable to shareholders was HKD 109 million, reflecting a 6% decline year-on-year [1]

Core Viewpoint - Guangnan Group (01203) reported a revenue of HKD 9.452 billion for the first three quarters, representing a year-on-year increase of 10% while the profit attributable to shareholders decreased by 6% to HKD 109 million [1] Financial Performance - Revenue for the first three quarters reached HKD 9.452 billion, marking a 10% increase compared to the previous year [1] - Profit attributable to shareholders was HKD 109 million, reflecting a 6% decrease year-on-year [1]

Core Insights - The company reported a consolidated revenue of HKD 9.452 billion for the first three quarters of 2025, representing a 10% increase compared to the same period last year [1] - The company's attributable profit decreased by 6% year-on-year to HKD 109 million [1] Segment Performance - The food biotechnology segment generated revenue of HKD 7.836 billion, an 11% increase year-on-year, but the segment profit (excluding share of associates) fell by 12% to HKD 138 million [1] - The company maintained its slaughtering operations in the Greater Bay Area, with a live pig slaughter volume of approximately 2.34 million heads, but faced a decline in operating profit due to intensified regional competition and price adjustments [1] - The market share for live pigs supplied to Hong Kong decreased to 48% from 49% year-on-year, leading to a reduction in profits from the live pig distribution business [1] - The company is expanding its food wholesale and retail operations in Hong Kong, currently operating 19 retail stores [1] - The performance of the joint venture in live pig breeding and sales slowed down due to falling pig prices in the third quarter, with the company's share of profits from associates amounting to HKD 18.91 million [1] - After accounting for the share of profits from associates, the segment profit for food biotechnology was HKD 157 million, a decrease of HKD 8.92 million or 5% year-on-year [1]

Financial Performance - For the first three quarters of 2025, the company's unaudited consolidated revenue was HKD 9.45 billion, an increase of 10% compared to HKD 8.58 billion in the same period last year[7]. - The unaudited consolidated profit attributable to shareholders for the same period was HKD 108.84 million, a decrease of 6% from HKD 115.82 million year-on-year[4]. - The food biotechnology segment generated revenue of HKD 7.84 billion, an increase of 11% year-on-year, but the segment profit (excluding share of profits from associates) decreased by 12% to HKD 138 million[8]. - The company maintained a total asset value of HKD 5.08 billion, reflecting a 3% increase from HKD 4.94 billion as of December 31, 2024[4]. - The equity attributable to shareholders rose by 4% to HKD 2.70 billion compared to HKD 2.59 billion at the end of 2024[4]. - The tinplate business produced and sold 240,000 tons of products, representing increases of 9% and 12% respectively, with segment profit rising by 81% to HKD 59.29 million[9]. - The company recorded a valuation gain of HKD 30,000 on investment properties, a significant improvement from a valuation loss of HKD 6.75 million in the previous year[10]. Market Challenges - The company continues to face challenges in the food biotechnology business due to fluctuations in pork prices and increased competition in the market[11]. - The overall market share for live pig distribution in Hong Kong decreased to 48%, down from 49% in the same period last year[8]. Retail Operations - The company is expanding its retail operations in Hong Kong, currently operating 19 retail stores[8].

Core Viewpoint - Guangnan Group (01203) announced significant changes in its board of directors effective from October 30, 2025, which may impact the company's governance structure and operational leadership [1] Group 1: Board Changes - Executive Director Yang Zhe has been reassigned from General Manager to Vice Chairman of the Board, while continuing to serve as Acting Chairman and Acting Chairman of the Nomination Committee [1] - Long Wenfang has been appointed as the Executive Director and General Manager of the company [1] - Zhou Hongji has resigned as Executive Director due to work adjustments but will continue in his roles as Chief Financial Officer, Company Secretary, and Authorized Representative under Listing Rule 3.05 [1]